BRECIS Program Schedule
| Monday April 13, 2015 | |
| Session 1: Epidemiology and Biology Moderators: Naser Elkum and Abdelilah Aboussekhra |
|
| 07.00 – 08.00 | Registration and refreshments |
| 08.00 – 08.05 | Welcome note Davide Bedognetti Director Tumor Biology, Immunology, and Therapy Section, Sidra Medical and Research Center, Qatar |
| 08.05 – 08.25 | Breast cancer control in Qatar Salha Boujassoum Al Badar Senior Consultant Hematology/Oncology, National Center for Cancer and Research, Hamad Medical Corporation, Qatar |
| 08.25 – 08.30 | Questions and answers |
| 08.30 – 08.50 | Triple negative and inflammatory breast cancer in Arab countries: A clue for personalized therapy Hammouda Boussen Professor, Department of Medical Oncology, A Mami Hospital, Tunisi |
| 08.50 – 08.55 | Questions and answers |
| 08.55 – 09.15 | Breast cancer in Arab Populations: The search for genes associated with aggressive form Lotfi Chouchane Professor of Genetic Medicine, Weill Cornell Medical College- Qatar, Qatar |
| 09.15 – 09.20 | Questions and answers |
| 09.20 – 09.40 | Mechanisms of tumor microenvironmental hypoxia-induced immune resistance Salem Chouaib Director, Integrated Research Cancer Institute, Gustave Roussy, France |
| 09.40 – 09.45 | Questions and answers |
| 09.45 – 10.00 | QNRF funding in medical research  Thenaa Said Program Manager, Biomedical and Health Sciences, Qatar National Research Fund, Qatar |
| 10.00 – 10.05 | Questions and answers |
| 10.05 – 10.25 | Comfort Break |
| 10.25 – 10.45 | Alterations of the tumor microenvironment by HER-2-neu-induced CREB activation and localization and hypoxia in mammary carcinoma: CREB as a novel therapeutic target for this disease? Barbara Seliger Professor, Martin Luther University Halle-Wittenberg, Germany |
| 10.45 – 10.50 | Questions and answers |
| 10.50 – 11.10 |
Expression profiling of inflammatory breast cancer Francois Bertucci Professor, Institut Paoli-Calmettes, Université de la Méditerranée, France |
| 11.10 – 11.15 | Questions and answers |
| 11.15 – 11.35 | Identification of novel master regulators of inflammatory breast cancer by system biology approaches Michele Ceccarelli Senior Scientist, Qatar Computing Research Institute, Qatar |
| 11.35 – 11.40 | Questions and answers |
| 11.40 – 12.00 | Dendritic cells and breast cancer Karolina Palucka Professor and associate director of cancer immunology, The Jackson Laboratory, USA |
| 12.00 – 12.05 | Questions and answers |
| 12.05 – 13.10 | Lunch and poster viewing |
| Oral Abstract session 1 Moderator: Emmanuel Akporiaye |
|
| 13.10 – 13.22 | Foxp3 expression in breast cancer patient from Qatar: Survival analysis Mahmoud Mohamed Weill Cornell Medical College-Qatar, Qatar |
| 13.22 – 13.25 | Questions and answers |
| 13.25 – 13.37 | Clinico-pathological and transcriptomic determinants of SLFN11 expression in invasive breast carcinoma Gabriele Zoppoli Department of Internal Medicine (DiMI), University of Genova, Italy |
| 13.37 – 13.40 | Questions and answers |
| 13.40 – 13.52 | The sialyl-glycolipid SSEA4 marks a subpopulation of chemotherapy resistant breast cancer cells with mesenchymal features Andrea Aloia Institute for Molecular Health Sciences, ETH Zurich, Switzerland /Miltenyi Biotec GmbH, Germany |
| 13.52 – 13.55 | Questions and answers |
| 13.55 – 14.05 | Comfort Break |
| Session 2: Biomarkers Moderators: Mohammed Haris and Sandra Demaria |
|
| 14.05 – 14.25 | Prognostic and predictive role of tumour-infiltrating lymphocytes in breast cancer Carsten Denkert Head, Translational Cancer Research Group at the Institute of Pathology, Charite University, Germany |
| 14.25 – 14.30 | Questions and answers |
| 14.30 – 14.50 | The Qatari breast cancer immunoscore project: A road map of what we know Shahinaz Bedri Assistant Professor of Pathology and Laboratory Medicine, Weill Cornell Medical College-Qatar, Qatar |
| 14.50 – 14.55 | Questions and answers |
| 14.55 – 15.15 | Serologic identification of tumor antigen in breast cancer Sam Hanash Director, Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer, University of Texas MD Anderson Cancer Center, USA |
| 15.15 – 15.20 | Questions and answers |
| 15.20 – 15.45 | Biomarkers of response to cancer immunotherapy Davide Bedognetti Director Tumor Biology, Immunology, and Therapy Section, Sidra Medical and Research Center, Qatar |
| 15.45 – 15.50 | Questions and answers |
| 15.50 – 16.10 | Breast cancer immune-subtypes and prognostic implications Lance Miller Core Director, Comprehensive Cancer Center, Wake Forest School of Medicine, USA |
| 16.10 – 16.15 | Questions and answers |
|
|
|
| Tuesday April 14, 2015 | |
| Session 3: Therapeutics (clinical and preclinical studies) Moderators: Alexander Knuth and Mario Roberto Sertoli |
|
| 07.00 – 08.00 | Registration and refreshments |
| 08.00 – 08.05 | Welcome note and keynote speaker introduction Emmanuel Akporiaye Division Chief Experimental Biology, Sidra Medical and Research Center, Qatar |
| 08.05 – 08.35 | KEYNOTE LECTURE: Cancer Immunotherapy Trials Network: High-priority immunotherapy agents in development Martin Cheever Director, Cancer Immunotherapy Trials Network, Member, Fred Hutchinson Cancer Research Center, USA |
| 08.35 – 08.55 | Generating immunity to breast cancer Nora Disis Professor, Department of Medicine, University of Washington, USA |
| 08.55 – 09.00 | Questions and answers |
| 09.00 – 09.20 | The PD-1 pathway: A therapeutic target in breast cancer Leisha Emens Associate Professor of Oncology, John Hopkins Medicine, USA |
| 09.20 – 09.25 | Questions and answers |
| 09.25 – 09.45 | Clinical development of HER2-derived peptide vaccines Elizabeth Mittendorf Associate Professor, Department of Surgical OncologyThe University of Texas MD Anderson Cancer Center, USA |
| 09.45 – 09.50 | Questions and answers |
| 09.50 – 10.10 | Immuno-Oncology clinical studies: The model of breast cancer Giuseppe Curigliano Co-Chair of the Division of Medical Oncology, European Institute of Oncology, Italy |
| 10.10 – 10.15 | Questions and answers |
| 10.15 – 10.35 | Comfort Break |
| 10.35 – 10.55 | Innate immunotherapy to enhance the efficacy of tumor targeting antibodies including trastruzumab for HER2+ breast cancer Holbrook Kohrt Assistant Professor, Stanford School of Medicine, USA |
| 10.55 – 11.00 | Questions and answers |
| 11.00 – 11.20 | Adoptive T-cell transfer in breast cancer patients - experiences from a phase 1/2 trial Florian Schuetz Deputy Director, Women´s Hospital, Heidelberg University, Germany |
| 11.20 – 11.25 | Questions and answers |
| Oral Abstract session 2 Moderator: Emmanuel Akporiaye |
|
| 11.25 – 11.37 | CTLA-4 checkpoint blockade in breast cancer: A case in point report Chiara Dellepiane IRCCS San Martino Institute, Genoa University, Italy |
| 11.37 – 11.40 | Questions and answers |
| 11.40 – 11.52 | Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients David Page Memorial Sloan Kettering Cancer Center, USA |
| 11.52 – 12.00 | Questions and answers |
| 12.00 – 12.12 | Long-term in vivo expression of trastuzumab following intramuscular electrotransfer of the encoding DNA in mice Kevin Hollevoet Laboratory for Therapeutic and Diagnostic Antibodies, Leuven University, Belgium |
| 12.12 – 12.15 | Questions and answers |
| 12.15 – 12.27 | Immune profiling in human breast cancers using high-sensitivity detection and analysis predicts outcome: longitudinal studies Brendon Coventry University of Adelaide, Australia |
| 12.27 – 12.30 | Questions and answers |
| 12.30 – 12.35 | Travel Award Ceremony |
| 12.35 – 13.35 | Lunch and poster rviewing |
| 13.35 – 13.55 | In situ vaccination by radiation in breast cancer Sandra Demaria Professor of Pathology and Radiation Oncology, New York University, USA |
| 13.55 – 14.00 | Questions and answers |
| 14.00 – 14.20 | Alpha-TEA, a novel cancer therapeutic: Journey from the bench to the clinic Emmanuel Akporiaye Division Chief Experimental Biology, Sidra Medical and Research Center, Qatar |
| 14.20 – 14.25 | Questions and answers |
| 14.25 – 14.35 | Closing remarks Emmanuel Akporiaye Division Chief Experimental Biology, Sidra Medical and Research Center, Qatar |
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
